Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PENTETATE CALCIUM TRISODIUM vs CUPRIMINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Pentetate calcium trisodium is a chelating agent that forms stable complexes with divalent and trivalent heavy metal ions, such as plutonium, americium, and curium. It enhances the urinary elimination of these metals by increasing the rate of dissociation from tissues and promoting renal excretion.
Chelates copper, forming a stable complex that is excreted renally, reducing systemic copper accumulation.
FDA-approved for the treatment of known or suspected internal contamination with plutonium, americium, or curium to increase the rate of elimination.,Off-label: treatment of internal contamination with other transuranic elements, such as californium, einsteinium, and berkelium; also used for iron overload in transfusion-dependent anemias.
Wilson disease,Cystinuria,Rheumatoid arthritis (off-label)
1 g (one vial) intravenously over 1 hour once daily for up to 5 days.
250-500 mg orally 4 times daily, titrated to maintain urinary copper excretion >2 mg/day. Maximum: 2 g/day.
Terminal elimination half-life is approximately 0.6-0.8 hours in patients with normal renal function.
Terminal half-life: 4–6 hours. Clinical context: After discontinuation, urinary copper excretion declines within 2–3 hours but may persist for several days due to tissue redistribution.
Pentetate calcium trisodium is not metabolized; it is excreted unchanged in the urine via glomerular filtration and tubular secretion within 24 hours.
Metabolized by oxidation and reduction; primarily renal elimination.
Primarily renal elimination via glomerular filtration; >90% of absorbed dose excreted unchanged in urine within 24 hours.
Renal: ~80% as unchanged drug, biliary/fecal: <5%
Negligible (<5%); primarily binds to plasma metal ions rather than proteins.
~70% bound, primarily to serum albumin.
Approximately 0.2-0.3 L/kg, indicating mainly extracellular distribution with minimal intracellular penetration.
Vd: 0.5–1.0 L/kg (approximately 70 L in adults). Indicates distribution into total body water with moderate tissue binding.
Not applicable; administered exclusively intravenously; oral bioavailability is negligible (<1%) due to poor absorption and gastrointestinal degradation.
Oral: Approximately 40–70% (variable, reduced by food, especially high-protein meals; administration on empty stomach recommended).
No dose adjustment recommended; use with caution in severe renal impairment (GFR <30 m L/min) due to potential for accumulation.
Contraindicated in severe renal impairment (GFR <30 m L/min). For GFR 30-60 m L/min: reduce dose by 25-50%. Monitor urinary copper and adjust accordingly.
No specific dose adjustment provided in labeling; use with caution in severe hepatic impairment.
No specific adjustment for Child-Pugh class A or B; use with caution in severe hepatic impairment (Child-Pugh C) due to hepatotoxicity risk. Monitor liver function.
Children: 14 mg/kg intravenously over 1 hour once daily; maximum 1 g/dose.
10-20 mg/kg/day orally divided into 2-4 doses; typical starting dose 15 mg/kg/day for Wilson disease (max 1 g/day). Titrate based on urinary copper.
No specific dose adjustment; start at lower end of dosing range due to potential for decreased renal function.
Start at lower end of dosing range (250 mg twice daily) due to age-related renal decline; monitor renal function and copper levels.
None.
WARNING: CUPRIMINE can cause severe bone marrow depression leading to aplastic anemia, leukopenia, thrombocytopenia, and agranulocytosis. Deaths have occurred. Monitor blood counts closely.
May cause depletion of essential trace metals (e.g., zinc, manganese) with prolonged use; monitor serum zinc levels during therapy. Use with caution in patients with impaired renal function, as drug accumulation may occur. Inhalation of pentetate calcium trisodium aerosol (for pulmonary contamination) may cause bronchospasm.
Bone marrow suppression, renal toxicity (proteinuria, hematuria), lupus-like syndrome, myasthenia gravis-like syndrome, rash, and hypersensitivity reactions. Monitor renal function, blood counts, and urinalysis regularly.
Hypersensitivity to pentetate calcium trisodium or any component of the formulation.
History of penicillamine-related aplastic anemia or agranulocytosis; concurrent gold therapy, antimalarial drugs, or immunosuppressants; rheumatoid arthritis patients with renal insufficiency.
No specific food interactions are known. Patients should maintain adequate hydration and follow a balanced diet. Avoid excessive intake of calcium-containing foods or supplements unless directed by a healthcare provider, as calcium may interfere with chelation.
Take on an empty stomach. Avoid food, especially milk, and any mineral supplements (iron, zinc, calcium) for at least 1 hour before and 2 hours after dosing, as they reduce absorption. Alcohol should be avoided due to potential hepatotoxicity.
Pentetate calcium trisodium is a chelating agent used for specific heavy metal poisonings. No controlled human studies exist. Animal studies indicate no directly observed teratogenicity, but caution is warranted. Fetal risk cannot be excluded in any trimester due to potential maternal toxicity and chelation of essential minerals.
First trimester: High risk of congenital anomalies including cutis laxa, micrognathia, limb deformities, and CNS defects. Second trimester: Continued risk of fetal harm, potential for growth restriction. Third trimester: Risk of fetal copper deficiency and associated neurological impairment. Pregnancy category D.
No human data exist regarding excretion in breast milk. M/P ratio unknown. The manufacturer recommends cautious use due to potential for excretion and adverse effects on nursing infant. Consider alternative therapy if possible.
Excreted in breast milk. M/P ratio not established. Contraindicated in breastfeeding due to potential for severe adverse effects (hypersensitivity, bone marrow suppression) in the infant.
No established pharmacokinetic studies in pregnancy. No specific dose adjustment recommendations. However, altered renal clearance and expanded plasma volume may affect drug elimination. Use the lowest effective dose for the shortest duration, guided by clinical response and maternal tolerance.
No standard dose adjustment recommended; use lowest effective dose. Monitor serum copper to maintain therapeutic levels due to altered pharmacokinetics in pregnancy (increased volume of distribution, renal clearance).
Administer IV slowly (over at least 1 hour) to minimize local irritation. Monitor renal function and serum electrolytes (especially calcium, magnesium, potassium) before and during therapy. Do not use in patients with significant renal impairment (Cr Cl <30 m L/min) unless benefit outweighs risk. May cause transient hypotension; ensure adequate hydration. Contraindicated in patients with known hypersensitivity to EDTA. Prolonged use can lead to trace element deficiencies.
Monitor for proteinuria and hematuria; perform urinalysis weekly initially, then monthly. Penicillamine can cause bone marrow suppression; obtain baseline CBC and differential, then monitor every 2 weeks for first 6 months, then monthly. Drug-induced lupus and myasthenia gravis are rare but serious autoimmune adverse effects. Avoid in patients with a history of penicillin allergy due to potential cross-sensitivity. Administer on an empty stomach at least 1 hour before or 2 hours after meals to enhance absorption. Dose adjustments needed in renal impairment. Pyridoxine (vitamin B6) supplementation (25-50 mg/day) is recommended to prevent deficiency caused by penicillamine. For Wilson disease, monitor 24-hour urinary copper excretion to guide therapy.
This medication is used to treat poisoning from radioactive substances or heavy metals.,Tell your doctor if you have kidney problems, heart disease, or are pregnant or breastfeeding.,You will need regular blood tests to check kidney function and mineral levels.,Report symptoms like fever, chills, muscle cramps, or pain at the injection site.,Do not take any other medications or supplements without consulting your doctor.
Take this medication on an empty stomach, at least 1 hour before or 2 hours after meals.,Do not skip doses; take exactly as prescribed and do not double up if a dose is missed.,Report any signs of allergy promptly: rash, itching, fever, joint pain, or swollen lymph nodes.,Contact your doctor immediately if you experience easy bruising, bleeding, or signs of infection such as fever or sore throat.,Inform your doctor about any planned vaccinations; avoid live vaccines while on this medication.,You may need regular blood and urine tests to monitor for side effects.,If you are taking iron supplements or other mineral supplements, take them at least 2 hours apart from this medication to prevent reduced absorption.,Use effective contraception if you are of childbearing age; this drug can harm an unborn baby.,Avoid alcohol as it may increase the risk of liver toxicity.,Notify your dentist about your medication history before any dental procedures.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PENTETATE CALCIUM TRISODIUM vs CUPRIMINE, answered by our medical review team.
PENTETATE CALCIUM TRISODIUM is a Chelating Agent that works by Pentetate calcium trisodium is a chelating agent that forms stable complexes with divalent and trivalent heavy metal ions, such as plutonium, americium, and curium. It enhances the urinary elimination of these metals by increasing the rate of dissociation from tissues and promoting renal excretion.. CUPRIMINE is a Chelating Agent that works by Chelates copper, forming a stable complex that is excreted renally, reducing systemic copper accumulation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PENTETATE CALCIUM TRISODIUM and CUPRIMINE depend on the specific clinical indication. These are both Chelating Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PENTETATE CALCIUM TRISODIUM is: 1 g (one vial) intravenously over 1 hour once daily for up to 5 days.. The standard adult dose of CUPRIMINE is: 250-500 mg orally 4 times daily, titrated to maintain urinary copper excretion >2 mg/day. Maximum: 2 g/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PENTETATE CALCIUM TRISODIUM and CUPRIMINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PENTETATE CALCIUM TRISODIUM is classified as Category C. Pentetate calcium trisodium is a chelating agent used for specific heavy metal poisonings. No controlled human studies exist. Animal studies indicate no directly observed teratogen. CUPRIMINE is classified as Category C. First trimester: High risk of congenital anomalies including cutis laxa, micrognathia, limb deformities, and CNS defects. Second trimester: Continued risk of fetal harm, potential . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.